Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LIM homeobox protein 2 (LHX2) is a transcription factor that belongs to the LIM-homeodomain protein family, characterized by the presence of a homeobox DNA-binding domain and two LIM domains which mediate protein–protein interactions. LHX2 regulates gene expression by functioning as a transcriptional activator or repressor depending on cellular context. It plays crucial roles in neural induction, morphogenesis, differentiation of lymphoid and neural cells, eye and hair development, olfactory sensory neuron specification, liver differentiation, and hematopoiesis. In bone, LHX2 acts as a negative regulator of osteoclast differentiation and is involved in bone remodeling by interacting with signaling molecules such as c-Fos. LHX2 dysfunction or altered expression is associated with developmental disorders and may contribute to pathological bone loss, but it is not currently a direct drug target and no approved pharmacological modulators are available[1][2][3][6].
Not applicable (no direct drug modulators known as of now); LHX2 modulates biological pathways by acting as a transcriptional activator or repressor, depending on context and binding partners[6][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LIM homeobox protein 2 (LHX2).